In early trading today, A-Shares continued to fluctuate and adjust, but the willingness to go north to copy the bottom of funds was still strong. After yesterday’s net purchase of more than 10 billion yuan, there was another net inflow of 3.178 billion yuan this morning.
On the market, the stock market is the main market, tourism, state-owned assets, hotels, restaurants, Baijiu and other sectors are relatively active.
the tourism sector bucked the trend
The tourism sector rose suddenly in the morning and opened higher against the trend. The sector index rose by nearly 5% in the session, a new high in half a year, and the half day transaction exceeded the whole day transaction yesterday. Many stocks such as Xi’An Qujiang Cultural Tourism Co.Ltd(600706) , Utour Group Co.Ltd(002707) , Yunnan Tourism Co.Ltd(002059) , China United Travel Co.Ltd(600358) also rose strongly. Both Huaxia tourism ETF and Fuguo tourism ETF once rose nearly 4%, ranking the top two. Hong Kong Tourism stocks also rose sharply. Gudou holdings soared by more than 17%, Ctrip group soared by more than 9%, and Tongcheng travel and Fosun tourism culture rose sharply.
On the news side, the State Council issued the “14th five year plan” for tourism development, proposing innovative tourism consumption scenarios and actively cultivating new modes of tourism consumption. Promote the innovation of tourism e-commerce and promote Wuxi Online Offline Communication Information Technology Co.Ltd(300959) complementary and integrated development of tourism consumption advantages. Support the development of shared tourism consumption, encourage the development of rental apartments, shared cars, remote car return and other services suitable for self driving tourism and leisure vacation, and develop contactless tourism consumption according to local conditions. We will actively develop night consumption and encourage cultural and tourist venues to extend their opening hours on the basis of ensuring safety.
The plan also proposes to timely study and judge the situation of covid-19 pneumonia epidemic prevention and control outside China and the development and changes of the international environment, scientifically adjust the management measures for relevant personnel to come to China, and actively build a healthy, safe and orderly order of personnel exchanges between China and foreign countries on the premise of ensuring epidemic prevention safety. Timely launch the inbound tourism promotion action and issue the inbound tourism development support policies.
Previously, affected by multiple factors such as the macroeconomic situation and covid-19 epidemic, China’s tourism market was facing great downward pressure. In the third quarter of 2021, the total number of Chinese tourists decreased by 18.3% year-on-year, and the inbound tourism market was in a state of overall stagnation. With the heavy release of tourism top-level design and planning, the inbound tourism market is expected to reopen, which will accelerate the recovery of the whole tourism industry.
According to the report “analysis of tourism economic operation in 2021 and development forecast in 2022” recently released by China Tourism Research Institute, the number of Chinese tourists is expected to reach 3.98 billion in 2022, and China’s tourism revenue is 3.81 trillion yuan, an increase of 16% and 27% respectively year-on-year. The number of inbound and outbound tourists is expected to increase by 20% year-on-year.
Guosen Securities Co.Ltd(002736) believes that the 14th five year plan for tourism promotes cross-border tourism step by step, and the long-term prospect of aviation is good. After the emergence of vaccines and specific drugs at the same time, it is only a matter of time for mankind to overcome the epidemic. When a strong boom is expected, the share price of aviation stocks is likely to remain active. It is undeniable that the short-term prosperity of civil aviation may still be disturbed by the sporadic epidemic, but the prosperity of the industry is highly expected after the epidemic subsides completely. The boom brought by the supply and demand reversal is industrial, and large and small airlines will benefit fully. From the perspective of valuation, Pb valuation of airlines is near the historical center, and there is still room for improvement. It is recommended to Air China Limited(601111) , China Southern Airlines Company Limited(600029) , China Eastern Airlines Corporation Limited(600115) , Spring Airlines Co.Ltd(601021) , Juneyao Airlines Co.Ltd(603885) .
pharmaceutical stocks fall into huge differences
As for the strong pharmaceutical stocks in the early stage, there are huge differences between ah stocks today. On the one hand, the beneficiary drug patent pool organization announced that it had signed agreements with 27 generic drug manufacturing companies. Among them, five Chinese pharmaceutical enterprises were shortlisted in the agreement list, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Shijiazhuang Longze pharmaceutical and Shanghai deseno were licensed to produce molnupiravir API and finished drug at the same time, and Langhua pharmaceutical under viabio was licensed to produce molnupiravir API.
Molnupiravir is the world’s first oral small molecule covid-19 drug jointly developed by MSD and Ridgeback. It has shown activity in many preclinical sars-cov-2 virus infection prevention, treatment and transmission prevention models. In November 2021, the British drug and health products Regulatory Authority (MHRA) took the lead in approving molnupiravir to be listed for the treatment of mild to moderate covid-19 adult patients with severe illness and high risk of hospitalization. Molnupiravir became the first approved oral covid-19 drug in the world. In December, the US Food and Drug Administration (FDA) also granted the drug emergency use authorization (EUA).
Stimulated by this positive situation, Brightgene Bio-Medical Technology Co.Ltd(688166) opened 20% of the word limit, and Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) opened once. Hong Kong stocks opened higher sharply. At one time, they soared by more than 37%, half day transactions exceeded six times of yesterday’s full day transactions, and Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) H shares also soared by more than 12%.
On the other hand, Changchun High And New Technology Industries (Group) Inc(000661) known as the “northeast medicine Mao” fell again today, which is the third consecutive limit in recent days. The stock price hit a new low in nearly two and a half years, and the high point of the market value evaporated nearly 130 billion yuan.
This caused some panic among investors in pharmaceutical stocks. After the opening of trading, Asahi biology, Zhejiang Orient Gene Biotech Co.Ltd(688298) , Nanjing Hicin Pharmaceutical Co.Ltd(300584) and other stocks fell unilaterally to the limit of 20%, and nearly 20 stocks such as Jiangxi Fushine Pharmaceutical Co.Ltd(300497) , Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , Sailong Pharmaceutical Group Co.Ltd(002898) fell by the limit or more than 10%.
ETFs such as medicine, medical devices, medical care and biomedicine all led the decline. Most Hong Kong Pharmaceutical stocks also fell. Geli pharmaceutical once plunged by more than 21%, Shanghai Junshi Biosciences Co.Ltd(688180) also plunged by more than 16%, xingkerong pharmaceutical fell by more than 11%, and Xiansheng pharmaceutical, tengshengbo pharmaceutical and Cansino Biologics Inc(688185) biology also fell one after another.
Changchun High And New Technology Industries (Group) Inc(000661) the day before the source of the sharp decline, the centralized volume procurement document of diclofenac and other drugs of Guangdong alliance released on the website of Guangdong Pharmaceutical Trading Center showed that a variety of recombinant human growth hormone were in the centralized procurement catalogue, including the recombinant human growth hormone injection of Changchun kinsay pharmaceutical, a holding subsidiary of Changchun High And New Technology Industries (Group) Inc(000661) , with a price reduction of about 70%.
Yesterday’s Dragon and tiger list data showed that institutions were still selling Changchun High And New Technology Industries (Group) Inc(000661) at a large sale. Among the top five business departments with the largest sales amount, four institutional seats were on the list, with a total sales of 170 million yuan. However, northbound capital increased its position by Changchun High And New Technology Industries (Group) Inc(000661) more than 210000 shares on Monday and more than 110000 shares on Tuesday. At the first limit on Wednesday, it bottomed out by nearly 790000 shares at a total cost of about 260 million yuan. At present, the whole line is deeply locked up.
In addition, after the continuous sharp decline, whether the stocks pledged by major shareholders will burst, this severe form appears in front of investors again. Investors have asked on the interactive platform that nearly 30 million shares reached the closing line on January 20. Will they be closed? Changchun High And New Technology Industries (Group) Inc(000661) today’s reply said that the pledge of relevant shares of major shareholders is the pledge guarantee provided for loans from relevant banks, which is not completely consistent with the setting of the closing line of pledge type repurchase transaction. The company will remind shareholders to pay full attention to the fluctuation of stock price and avoid relevant risks.
At noon on the 21st, Changchun High And New Technology Industries (Group) Inc(000661) announced that the actual time interval of the company’s share repurchase is from December 3, 2021 to January 21, 2022. It has accumulated 2473200 shares of the company through centralized bidding transaction through the special securities account for repurchase, accounting for 0.61% of the total share capital of the company, of which the highest transaction price is 308.35 yuan / share and the lowest transaction price is 184.36 yuan / share, The total transaction amount is RMB 600 million (including transaction expenses). So far, the repurchase plan of the company has been implemented.
